Literature DB >> 9495297

Expression of costimulatory molecules B7-1, B7-2, and CD40 in the heart of patients with acute myocarditis and dilated cardiomyopathy.

Y Seko1, N Takahashi, S Ishiyama, T Nishikawa, T Kasajima, M Hiroe, S Suzuki, S Ishiwata, S Kawai, M Azuma, H Yagita, K Okumura, Y Yazaki.   

Abstract

BACKGROUND: In patients with acute myocarditis and dilated cardiomyopathy (DCM), we previously reported that antigen-specific T cells infiltrate the heart and play an important role in the myocardial damage involved. For antigen-specific T-cell activation to occur, it is necessary for T cells to receive a costimulatory signal provided by costimulatory molecules expressed on antigen-presenting cells (APCs) as well as the main signal provided by binding of T-cell receptors to the antigen. METHODS AND
RESULTS: To investigate the roles of the costimulatory molecules B7-1, B7-2, and CD40 in the development of acute myocarditis and DCM, we analyzed the expression of these antigens in the myocardial tissues of patients with acute myocarditis and DCM. We also examined the expression of a cytolytic factor, perforin, in the infiltrating cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, because both killer lymphocytes are thought to damage B7-1-expressing APCs. We found that B7-1, B7-2, and CD40 were moderately to strongly expressed in the cardiac myocytes of patients with acute myocarditis. Weak to moderate expression of these antigens was also found in the cardiac myocytes of patients with DCM. There was infiltration of perforin-expressing CTLs and NK cells in the myocardial tissues of patients with acute myocarditis and DCM.
CONCLUSIONS: Our findings strongly suggest that expression of B7-1, B7-2, and CD40 antigens on cardiac myocytes may make them APCs for CTLs and NK cells and that they may play an important role in the direct myocardial damage by these killer cells in acute myocarditis and DCM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9495297     DOI: 10.1161/01.cir.97.7.637

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

Review 1.  Influence of myocarditis on left ventricular function.

Authors:  K L Baughman
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

2.  Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies.

Authors:  K Murata; M C Dalakas
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 3.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

4.  Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis.

Authors:  Georgia Fousteri; Amy Dave; Bret Morin; Shaida Omid; Michael Croft; Matthias G von Herrath
Journal:  J Autoimmun       Date:  2011-02-17       Impact factor: 7.094

5.  Increases in circulating T lymphocytes expressing HLA-DR and CD40 ligand in patients with dilated cardiomyopathy.

Authors:  Atsuko Ueno; Kagari Murasaki; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

Review 6.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

7.  Critical contribution of CD28-CD80/CD86 costimulatory pathway to protection from Trypanosoma cruzi infection.

Authors:  Yasushi Miyahira; Masaharu Katae; Seiki Kobayashi; Tsutomu Takeuchi; Yoshinosuke Fukuchi; Ryo Abe; Ko Okumura; Hideo Yagita; Takashi Aoki
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

8.  Expression of CD80 and CD86 on B cells during coxsackievirus B3-induced acute myocarditis.

Authors:  Yanlan Huang; Bin Wei; Xingcui Gao; Yan Deng; Weifeng Wu
Journal:  Cent Eur J Immunol       Date:  2020-01-20       Impact factor: 2.085

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.